Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2013 (2013), Article ID 871476, 2 pages
http://dx.doi.org/10.1155/2013/871476
Case Report

Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript

1Hematology Unit and Bone Marrow Transplantation Center, “R. Binaghi” Hospital, Via Is Guadazzonis 3, 09126 Cagliari, Italy
2Hematology, Department of Medical Sciences, University of Cagliari, 09100 Cagliari, Italy

Received 4 June 2013; Accepted 27 June 2013

Academic Editors: E. Arellano-Rodrigo and K. Konstantopoulos

Copyright © 2013 Marianna Greco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Saglio, A. Guerrasio, C. Rosso et al., “New type of Bcr/Abl junction in Philadelphia chromosome—positive chronic myelogenous leukemia,” Blood, vol. 76, no. 9, pp. 1819–1824, 1990. View at Google Scholar · View at Scopus
  2. F. Pane, F. Frigeri, M. Sindona et al., “Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction),” Blood, vol. 88, no. 7, pp. 2410–2414, 1996. View at Google Scholar · View at Scopus
  3. A. Ohsaka, S. Hoshino, M. Kobayashi, H. Kudo, and R. Kawaguchi, “Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a),” British Journal of Haematology, vol. 118, no. 1, pp. 251–254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Pane, M. Intrieri, C. Quintarelli, B. Izzo, G. C. Muccioli, and F. Salvatore, “BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations,” Oncogene, vol. 21, no. 56, pp. 8652–8667, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. B. C. Mondal, S. Majumdar, U. B. Dasgupta, U. Chaudhuri, P. Chakrabarti, and S. Bhattacharyya, “E19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases,” Journal of Clinical Pathology, vol. 59, no. 10, pp. 1102–1103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Li, J. Yang, X. Chen et al., “A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript,” Cancer Genetics and Cytogenetics, vol. 176, no. 2, pp. 166–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Cea, G. Cirmena, A. Garuti et al., “A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib,” Leukemia Research, vol. 34, no. 9, pp. e240–e242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. E. Langabeer, S. L. McCarron, J. Kelly et al., “Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring,” Case Reports in Hematology, vol. 2012, Article ID 458716, 3 pages, 2012. View at Publisher · View at Google Scholar
  9. S. E. Langabeer, S. L. McCarron, P. Carroll, J. Kelly, M. O'Dwyer, and E. Conneally, “Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia,” Leukemia Research, vol. 35, no. 9, pp. e169–e170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. G. La Nasa, G. Caocci, R. Littera et al., “Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response totreatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients,” Experimental Hematology, vol. 41, no. 5, pp. 424–431, 2013. View at Google Scholar